Open AccessSodium–glucose cotransporter 2 inhibitor and sarcopenia in a lean elderly adult with type 2 diabetes: A case report
Author(s) -
Yasuda Megumi,
Iizuka Katsumi,
Kato Takehiro,
Liu Yanyan,
Takao Ken,
omura Kenta,
Mizuno Masami,
Yabe Daisuke
Publication year - 2020
Publication title -
journal of diabetes investigation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.089
H-Index - 50
eISSN - 2040-1124
pISSN - 2040-1116
DOI - 10.1111/jdi.13137
Subject(s) - medicine , ketosis , dapagliflozin , diabetes mellitus , glycated hemoglobin , type 2 diabetes , sarcopenia , diabetic ketoacidosis , insulin , glycemic , endocrinology , gastroenterology
A 70‐year‐old woman with type 2 diabetes was admitted to Gifu University Hospital, Gifu, Japan, because of ketosis. She was diagnosed with type 2 diabetes at age 49 years and started insulin therapy at age 57 years, which restored glycemic control. Insulin therapy was discontinued and oral antidiabetes drugs, including sodium–glucose cotransporter 2 inhibitor dapagliflozin, were initiated at age 69 years. Thereafter, her bodyweight declined from 40.0 kg to 29.8 kg in 12 months; glycated hemoglobin remained >8.0%. On admission to our hospital, her laboratory tests and computed tomography scan showed ketosis, insulinopenia, and the presence of dehydration and bacterial pneumonia. She also lost substantial bodyweight and developed sarcopenia. The current case shows the importance of patient assessment before sodium–glucose cotransporter 2 inhibitor initiation in the elderly.